From: Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment
Characteristic
No
%
No. of previous treatment lines
2
9
19.2
3
19
40.4
4
Regorafenib before TAS-102
Yes
28
59.6
Response to first-line chemotherapy
CR
1
2.1
PR
15
31.9
SD
22
46.8
PD